HOME >> BIOLOGY >> NEWS
Study pinpoints mechanism behind tamoxifen side effect

BOSTON Researchers at Dana-Farber Cancer Institute have identified the underlying mechanism that causes one of the unwanted side effects of tamoxifen. The study, published in the March 29 issue of Science, may help researchers home in on new medications that, like tamoxifen, reduce the risk of certain types of breast cancer, but do not carry tamoxifens potentially dangerous downside.

Tamoxifen was the first drug shown capable of reducing the chances of breast cancer development in some women at risk for the disease, says Myles Brown, MD, Dana-Farber researcher and the studys senior author. But many women have been reluctant to take it because of potential side effects. By understanding the basic mechanism by which the drug works, we can look for medications whose profile of effects is more advantageous to patients.

Tamoxifen is currently used to lower the risk of breast cancer recurrence in women whose breast cell growth is fueled by the hormone estrogen. In the breast, tamoxifen acts as an anti-estrogen, blocking the hormone from latching onto cells and delivering a growth signal. In some other parts of the body, however, tamoxifen and estrogen have similar effects: both substances help strengthen womens bones, for example, and may help keep their cardiovascular systems healthy.

Unfortunately, estrogen and tamoxifen also have a common detrimental effect a heightened risk of the development of endometrial cancer. A nationwide study is under way to determine whether a drug called raloxifene, which may reduce breast cancer risk without raising the risk of endometrial cancer, prevents breast cancer as effectively as tamoxifen does.

Both tamoxifen and raloxifene belong to a class of substances known as selective estrogen receptor modulators, or SERMs, which bind inside cells at the same receptors that estrogen does. In some types of cells, such as those in bones and the cardiovascular system, the effects of this binding are similar for
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
28-Mar-2002


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: